Based on the Novo Nordisk A/S stock forecast from 5 analysts, the average analyst target price for Novo Nordisk A/S is USD 159.02 over the next 12 months. Novo Nordisk A/S’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Novo Nordisk A/S is Bullish , which is based on 13 positive signals and 5 negative signals. At the last closing, Novo Nordisk A/S’s stock price was USD 102.63. Novo Nordisk A/S’s stock price has changed by -2.55% over the past week, -12.53% over the past month and -0.15% over the last year.
No recent analyst target price found for Novo Nordisk A/S
No recent average analyst rating found for Novo Nordisk A/S
Company Overview Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Read Less
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segmen...Read More
Frequently Asked Questions About Novo Nordisk A/S (NVO) Stock
Based on ratings from 5 analysts Novo Nordisk A/S's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 10 buy, sell and 1 hold ratings.
NVO stock's dividend yield is 1.29%.
Our analysis grades NVO stock's dividend yield at F. This means that NVO stock's dividend yield is above 29% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this NVO may be a poor dividend stock for its sector.
Based on targets from 5 analysts, the average taret price for NVO is USD 159.02 over the next 12 months. The maximum analyst target price is USD 163 while the minimum anlayst target price is USD 154.25.
NVO stock's Price/Earning ratio is 38.34.
Our analysis grades NVO stock's Price / Earning ratio at F. This means that NVO stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this NVO may be a overvalued for its sector.
The last closing price of NVO's stock was USD 102.63.
The most recent market capitalization for NVO is USD 499.24B.
Based on targets from 5 analysts, the average taret price for NVO is projected at USD 159.02 over the next 12 months.
This means that NVO's stock price may go up by +54.95% over the next 12 months.
We can't find any ETFs which contains Novo Nordisk A/S's stock.
As per our most recent records Novo Nordisk A/S has 69,260 Employees.
Novo Nordisk A/S's registered address is Novo Alle 1, Bagsvaerd, Denmark, 2880.
You can get more information about it from Novo Nordisk A/S's website at https://www.novonordisk.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Underpriced on cashflow basis
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Novo Nordisk A/S (NVO) Stock
Based on ratings from 5 analysts Novo Nordisk A/S's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 10 buy, sell and 1 hold ratings.
NVO stock's dividend yield is 1.29%.
Our analysis grades NVO stock's dividend yield at F. This means that NVO stock's dividend yield is above 29% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this NVO may be a poor dividend stock for its sector.
Based on targets from 5 analysts, the average taret price for NVO is USD 159.02 over the next 12 months. The maximum analyst target price is USD 163 while the minimum anlayst target price is USD 154.25.
NVO stock's Price/Earning ratio is 38.34.
Our analysis grades NVO stock's Price / Earning ratio at F. This means that NVO stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this NVO may be a overvalued for its sector.
The last closing price of NVO's stock was USD 102.63.
The most recent market capitalization for NVO is USD 499.24B.
Based on targets from 5 analysts, the average taret price for NVO is projected at USD 159.02 over the next 12 months.
This means that NVO's stock price may go up by +54.95% over the next 12 months.
We can't find any ETFs which contains Novo Nordisk A/S's stock.
As per our most recent records Novo Nordisk A/S has 69,260 Employees.
Novo Nordisk A/S's registered address is Novo Alle 1, Bagsvaerd, Denmark, 2880.
You can get more information about it from Novo Nordisk A/S's website at https://www.novonordisk.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NVO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
